Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of bevacizumab combined with vinorelbine in
treating patients who have stage IV breast cancer. Monoclonal antibodies such as bevacizumab
can locate tumor cells and either kill them or deliver tumor-killing substances to them
without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor
cells from dividing so they stop growing or die. Combining monoclonal antibody with
chemotherapy may kill more cancer cells